Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Metformin alters therapeutic effects in the BALB/c tumor therapy model

Fig. 2

Anti-carcinogenic effect of Metformin in the BALB-CTA. a The BALB/c 3 T3 cell transformation assay was performed according to the recommended protocol. In brief, cells were seeded in 6-well plates and treated with the tumor initiator MCA (0.5 μg/ml) on day 1–4 and the tumor promotor TPA (0.3 μg/ml) from day 8–21 in order to induce malignant cell transformation. Metformin was added additionally either chronical from day 1–42 or in the late phase of malignant cell transformation from day 32–42. On day 42, cells were fixed with methanol and stained with Giemsa solution for better visualization of cell foci. b Representative pictures and the number of type-III foci of 3 biological replicates (mean + SD) are shown. Statistical differences were calculated with a one-way ANOVA (post-hoc: Bonferroni) with * = (p < 0.05) vs. control

Back to article page